Chromosome 20q13.2 gain may predict intravesical recurrence after nephroureterectomy in upper urinary tract urothelial tumors

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 7004-7008

  Akao, Jumpei ^a   Matsuyama, Hideyasu ^a   Yamamoto, Yoshiaki ^a   Sasaki, Kohsuke ^a   Naito, Katsusuke ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CENTROSOME; CHROMOSOMAL INSTABILITY; CHROMOSOME 17; CHROMOSOME 20Q; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME ABERRATION; CONFIDENCE INTERVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; URINARY TRACT CARCINOMA;

AGED; AGED, 80 AND OVER; CENTROSOME; CHROMOSOMAL INSTABILITY; CHROMOSOMES, HUMAN, PAIR 20; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; URETERAL NEOPLASMS;

EID: 33845749146     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0825     Document Type: Article

References (27)

1. Messing EM, Catalona W. Urothelial tumors of the renal pelvis and ureter. Campbell's urology. 7th ed. Philadelphia: WB Saunders; 1998. p. 2383-410.
2. Hatch TR, Hefty TR, Barry JM. Time-related recurrence rates in patients with upper tract transitional cell carcinoma. J Urol 1988;140:40-1.
3. Sakamoto N, Naito S, Kotoh S, et al. Recurrence of bladder tumors following surgery for transitional cell carcinoma of the upper urinary tract. Eur Urol 1991;20:136-9.
4. Hisataki T, Miyao N, Masumori N, et al. Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology 2000;55:663-7.
5. Koga F, Nagamatsu H, Ishimaru H, Mizuo T, Yoshida K. Risk factors for the development of bladder transitional cell carcinoma following surgery for transitional cell carcinoma of the upper urinary tract. Urol Int 2001;67:135-41.
6. Kang CH, Yu TJ, Hsieh HH, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003;98:1620-6.
7. Matsui Y, Utsunomiya N, Ichioka K, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005;65:279-83.
8. Raman JD, Ng CK, Boorjian SA, Vaughan ED, Jr., Sosa RE, Scherr DS. Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int 2005;96:1031-5.
9. Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer 1988;62:2016-20.
10. Jones TD, Wang M, Eble JN, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005;11:6512-9.
11. Harris AL, Neal DE. Bladder cancer-field versus clonal origin. N Engl J Med 1992;326:759-61.
12. Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 2002;101:1-6.
13. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
14. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
15. Amira N, Rivet J, Soliman H, et al. Microsatellite instability in urothelial carcinoma of the upper urinary tract. J Urol 2003;170:1151-4.
16. Lingle WL, Barrett SL, Negron VC, et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A 2002;99:1978-83.
17. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 2003;63:1398-404.
18. Yamamoto Y, Matsuyama H, Furuya T, et al. Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer. Clin Cancer Res 2004;10:6449-55.
19. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag: 2002. p. 329-34.
20. Sen S, Zhou H, Zhang RD, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320-9.
21. Aust DE, Muders M, Kohler A, et al. Prognostic relevance of 20q13 gains in sporadic colorectal cancers: a FISH analysis. Scand J Gastroenterol 2004;39:766-72.
22. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-7.
23. Savelieva E, Belair CD, Newton MA, et al. 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells. Oncogene 1997;14:551-60.
24. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-93.
25. Tanner MM, Tirkkonen M, Kallioniemi A, et al. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1995;1:1455-61.
26. Diebold J, Mosinger K, Peiro G, et al. 20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization. J Pathol 2000;190:564-71.
27. Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999;86:1818-26.